WASHINGTON, DC - November 2, 2026 - No Patient Left Behind Executive Director Priscilla VanderVeer shared the following statement on the bipartisan Faster Clinical Trials Act introduced by Representatives Jake Auchincloss (D-MA) and Morgan Griffith (R-VA):
“We applaud Representatives Auchincloss and Griffith for introducing the bipartisan ‘Faster Clinical Trials Act,’ which would accelerate the development of new medicines, expand patient access to clinical trials, and strengthen America’s biomedical innovation ecosystem.
“Millions of people are living with diseases that do not have effective treatments or cures. We should be making a path to cures easier, and the Faster Clinical Trials Act would do just that.
“The legislation would create a ‘Center for Clinical Trial Innovation’ at the FDA to improve coordination across trial sites. It would give the FDA more authority to work with drugmakers during the R&D process. And it would bring trials to patients’ point of care, so they don’t have to travel to a trial site. Together, these reforms would make clinical trials faster, more accessible, and less costly.
“In a competitive global environment, this is exactly the kind of forward-looking policy we need to sustain U.S. leadership in biomedical innovation. It’s a welcome example of the good we can do by improving the R&D environment here at home, rather than pursuing narrow-minded efforts to block others abroad.
“We commend this bipartisan effort and urge Congress to pass the Faster Clinical Trials Act so new treatments and cures reach patients sooner.”
About No Patient Left Behind
No Patient Left Behind (NPLB) is a coalition of biotechnology innovators, investors, healthcare professionals, economists, and patient advocates working to ensure that patients have access to the medicines they need today and in the future. Learn more about NPLB’s latest initiatives at www.nopatientleftbehind.org.